Today: 27 June 2026
Seatrium share price stuck at S$2.11 as SGX reopens Monday; Feb 26 results loom
1 February 2026
1 min read

Seatrium share price stuck at S$2.11 as SGX reopens Monday; Feb 26 results loom

SINGAPORE, Feb 1, 2026, 15:44 SGT — The market has closed.

Seatrium Limited finished Friday unchanged at S$2.11, wrapping up the week with minimal action before trading resumes Monday. The share price fluctuated between S$2.10 and S$2.13, on volume around 7.84 million shares.

The steady close unfolded alongside a 0.5% drop in Singapore’s Straits Times Index on Friday, mirroring Wall Street’s losses from the previous night. Yangzijiang Shipbuilding, a marine sector stock within the index, slid 1.8%.

Timing is key now. Seatrium plans to publish its full-year 2025 financial results on Feb. 26 before the market opens, according to a filing with the Singapore Exchange. This gives investors a clear update after a quiet end to January.

The stock slipped roughly 0.5% compared to a week ago, measured by daily closing prices, despite finishing flat on the last session. That subtle decline leaves the stock exposed to sharp moves once trading kicks off again.

Energy prices are key to sentiment around offshore work. Brent closed Friday at $70.69 a barrel, while U.S. crude finished at $65.21. Traders are focused on rising tensions between the United States and Iran. “It’s really all about Iran right now,” John Kilduff of Again Capital said. Reuters

Traders headed into the weekend eyeing OPEC+. Five delegates told Reuters the group plans to maintain its hold on boosting oil output for March during Sunday’s meeting, following Brent’s climb above $70 a barrel.

Seatrium, known for building and repairing offshore and marine assets, has been highlighting its backlog and pipeline to shift investor attention away from isolated disputes. In a Q&A released Friday, the company revealed its net order book reached $16.6 billion as of end-September 2025, covering 24 projects with deliveries stretching to 2031. It also reported securing over $3 billion in new orders since that date.

Still, legal and project risks continue to trouble some investors. In a broker note released Friday, CGS International’s Lim Siew Khee and Meghana Kande maintained an “add” rating on the stock, setting a $2.67 target. Citi Research’s Luis Hilado also stuck to his “buy” call with a $2.65 target, despite news of arbitration proceedings involving Seatrium’s partner Aibel. The arbitration requests were lodged with the Stockholm Chamber of Commerce, the report noted. The Edge Singapore

Arbitrations often drag on, making outcomes tough to price. A loss for Seatrium—or a messy settlement—could squeeze margins and cash conversion right when investors want clear evidence that big-order execution is improving.

Monday’s main question: will oil and broader risk appetite hold up to keep offshore stocks buoyant, or will the market shift toward caution?

Seatrium is set to hold a results webcast at 11 a.m. Singapore time on Feb. 26, following the release of its FY2025 figures.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • Telix Pharmaceuticals and Two Australian Insider-Led Growth Stocks Highlighted
    June 27, 2026, 11:07 AM EDT. Telix Pharmaceuticals (ASX:TLX), a A$5.2 billion biopharmaceutical firm specializing in radiopharmaceuticals for cancer imaging and treatment, draws growth-focused investors despite ongoing losses. The company reported US$621.9 million revenue from Precision Medicine and relies heavily on its oncology pipeline with products like Illuccix and late-stage candidates TLX591 and TLX101. Key risks include high R&D costs, regulatory scrutiny, pricing pressures, and trial dependencies. Also featured are two Australian insider-led growth stocks identified by the Fast Growing Stocks With High Insider Ownership screener, highlighting firms with aligned management-shareholder interests amid mixed inflation and cautious central bank policies.

Latest articles

Generate Biomedicines stock ends week back above IPO price as volume jumps

Generate Biomedicines stock ends week back above IPO price as volume jumps

27 June 2026
Generate Biomedicines (NASDAQ:GENB) surged 13.7% since June 18 to close Friday at $16.47—above its $16 IPO price—with heavy volume and a $2.11B market cap, as investors weigh its $516.6M cash pile, ongoing clinical trial risks, and lack of product revenue, while sector momentum lifts biotech stocks.
Snowflake (NYSE:SNOW) finishes up for the week after Russell rebalance trading

Snowflake (NYSE:SNOW) finishes up for the week after Russell rebalance trading

27 June 2026
Snowflake Inc (NYSE:SNOW) surged 9.65% to $248.96 on Friday with trading volume five times the weekly average, driven by FTSE Russell’s U.S. index reconstitution, turning a negative week into a 7.2% gain since June 18, as investors await whether the stock can hold above its previous $225.95–$230.41 range when index-driven liquidity fades next week.
GameStop (NYSE:GME) holds close to cash levels after company guides for $600 million in EBITDA

GameStop (NYSE:GME) holds close to cash levels after company guides for $600 million in EBITDA

27 June 2026
GameStop surged 3.57% to $21.76 and jumped after hours as it forecast FY2026 adjusted EBITDA above $600 million, nearly doubling from 2025; with a $9.76 billion market cap now close to its $9.7 billion in cash, securities, digital assets, and collateral, investors are weighing whether GameStop’s cash-rich balance sheet can support equity while Ryan Cohen pursues an eBay bid.
ImmunityBio (NASDAQ:IBRX) trades after post-Russell spike with 46% more volume

ImmunityBio (NASDAQ:IBRX) trades after post-Russell spike with 46% more volume

27 June 2026
ImmunityBio surged 11.8% to $8.71 on Friday with volume tripling its average, as Russell index reconstitution took effect; Monday’s trading will reveal if demand persists or if the spike was driven by index flows, with no imminent company events and recent insider selling accounting for just 0.06% of Friday’s volume.
Texas Instruments stock: what to know after TXN dips, with jobs data and chip demand in focus
Previous Story

Texas Instruments stock: what to know after TXN dips, with jobs data and chip demand in focus

Reckitt Benckiser shares jump, but an ex-dividend reset looms on Monday
Next Story

Reckitt Benckiser shares jump, but an ex-dividend reset looms on Monday

Go toTop